CVS is about lose more than 40 million prescriptions Drugstore chain and pharmacy benefits manager CVS Health Corp cut its profit forecast for this year and projected weak growth for…
Johnson & Johnson is in talks to acquire the Swiss biotech company, Actelion, which develops drugs for rare diseases such as pulmonary arterial hypertension. Actelion share price has been steadily…
Will ‘Zero-Rating’ be AT&T’s Achilles heel in buying Time Warner? As AT&T Inc. and Time Warner Inc. seek government approval for their $85 billion megadeal, regulatory scrutiny may impede this…
Biogen Idec (NASDAQ: BIIB) grabbed all the next-day-headlines after officially announcing their exciting phase 1b clinical results in a peer-reviewed journal Nature in September 2016. To trace back, the encouraging…